PD-L1 overexpression

The patient subsequently received first-line treatment with nivolumab plus FOLFOX, achieving a marked radiological response...This case illustrates the potential benefit of immunotherapy in EBV-positive gastric cancer, even in the microsatellite-stable setting. The overlap of biomarkers in this patient may have contributed to immune response, highlighting the importance of comprehensive molecular profiling in GEA and supporting EBV status as a promising predictor of immunotherapy benefit.

Dexamethasone treatment was associated with reduced densities of CD86+ TAMs in brain metastases...The heterogeneity and frequent discordance of PD-L1 expression highlight its dynamic regulation and support individualized assessment of metastatic lesions prior to immunotherapy. Collectively, these findings support site-specific immune profiling and identify TAMs as promising therapeutic targets within the TME of CRC brain metastases.

First-line pembrolizumab monotherapy demonstrated favorable effectiveness and acceptable safety in patients with advanced NSCLC in real-world clinical practice in Vietnam. Clinical outcomes were particularly favorable in patients with high PD-L1 expression, non-squamous histology, and a history of smoking. Nevertheless, the survival benefit associated with non-squamous histology should be interpreted cautiously, given the limited number of patients with squamous histology. These findings support the use of pembrolizumab monotherapy in selected patient populations within resource-limited settings.

No significant correlation of PD-L1 with p16 positivity, lymph node metastases, or tumor grade was observed. High PD-L1 expression was observed in more than 80% of cases, regardless of HPV status, suggesting that targeted immunotherapy with PD-L1 inhibitors can be an effective treatment in the Indian subpopulation, especially in those with advanced-stage tumors.

Nivolumab was initiated after disease progression on everolimus, resulting in durable disease control for over 3 years. Immunohistochemistry revealed high PD-L1 expression and CD8+ T-cell infiltration within the primary tumor. Immune checkpoint inhibitors may be effective treatment options for malignant epithelioid angiomyolipoma with PD-L1 expression and CD8+ T-cell infiltration.

P=N/A, N=485, Shanghai pulmonary hospital; shanghai pulmonary hospital

Tumor PD-L1 is associated with better PFS and OS after ipilimumab + nivolumab. In the sarcomatoid/rhabdoid subset, lower CD25 (a marker of regulatory T cells) was associated with improved PFS, while increased neutrophil infiltration (CD66b+/MPO+) emerged as a novel feature of sarcomatoid/rhabdoid tumors, which may be harnessed for therapeutic benefit in this population.

Based on clinicians' practical deployment, the DHGN significantly reduced the operational complexity and computational requirements (P < 0.01) for model development and application in clinical settings. In conclusion, we proposed a clinician-friendly population graph model that fuses baseline clinical data with CT radiomics on widely available CPU hardware accurately stratifies NSCLC patients for immunotherapy benefits, potentially redefining benchmarks for non-invasive prognostic biomarkers and enabling broader clinical translation.

Silencing SH3PXD2A-AS1 reduced MYBL2/WTAP/PD-L1 signaling, decreased malignant phenotypes in vitro, and restored antitumor T-cell activity in humanized mouse models, whereas enforced MYBL2 or WTAP expression counteracted these effects. Collectively, these findings define an lncRNA-transcription factor-epitranscriptomic checkpoint that sustains PD-L1-mediated immune escape in NSCLC, and nominate SH3PXD2A-AS1 and its MYBL2/WTAP partners as potential biomarkers and therapeutic targets to improve responses to immune checkpoint inhibition.

The findings of this study demonstrated a potential dual role of USP35 in NSCLC, contributing to the targeted therapy of the cancer.

Two cycles of nivolumab plus ipilimumab were performed before discovering severe cervical spine pain. Here we show (1) robust CD3+ and CD20+ infiltration in primary tumors and metastases, with immune cells in direct contact with tumor cells or organized in lymphoid aggregates/tertiary lymphoid structures; (2) PD-L1 overexpression in sRCC and nodal metastasis but absent in post-immunotherapy bone lesions; (3) increased CD163+ macrophages in sRCC and metastases versus ccRCC. This case illustrates that ICIs can induce near-complete eradication of bone metastases; that bone is not an immune-exempt organ, with massive intratumoral immune cell infiltration; and that immediate immune-mediated tumor clearance prevents structural skeletal damage, which merits careful surveillance.

First-line ICI monotherapy and dual ICIs did not significantly improve OS, PFS, and ORR compared with EXTREME. However, a discernible trend suggested a potential survival benefit for ICIs in patients with high PD-L1 expression.